Kancera

Our vision is to develop pharmaceuticals that contribute to normalized lives for patients

New class of drugs for treatment of severe inflammatory conditions and resistant cancer

The fractalkine axis controls pro-inflammatory cells and cancer cells with precision

Our business

Kancera develops pharmaceuticals for life threatening diseases with high medical needs

Our science

Kancera develops a new class of drugs targeting the fractalkine axis

Our pipeline

Kancera’s two fractalkine blocking drug candidates are currently being studied in three ongoing clinical trials

CEO statement

"Having three clinical studies in the pipeline, all with potential to address medical needs in diseases with significant market opportunities, I feel very confident about Kancera’s opportunities."

Peter Selin, CEO Kancera

Press Releases

2023-11-17
Kancera provides operational update in connection with release of financial interim report for third quarter 2023
2023-11-17
Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851
2023-10-23
Kancera reports that the phase I study of KAND145 has received regulatory approval

Events

No upcoming events are currently in the calendar

Presentations

CEO Peter Selin presents Kancera’s Q3 2023 Interim Report